SeidlinSM, MarinelliLD, OshryE. 1946. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of thyroid. JAMA, 132:838–847.
2.
BeckerDV, SawinCT. 1996. Radioiodine and thyroid disease: the beginning. Semin Nucl Med, 26:155–164.
3.
HalnanKE. 1965. The place of non-surgical methods in diagnosis and management, and the long-term value of treatment of thyroid cancer. Br J Surg, 52:736–739.
4.
CooperDS, DohertyGM, HaugenBR, KloosRT, LeeSL, MandelSJ, MazzaferriEL, McIverB, PaciniF, SchlumbergerM, ShermanSI, StewardDL, TuttleRM. 2009. Revised management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroidsubmitted.
5.
MaenpaaHO, HeikkonenJ, VaalavirtaL, TenhunenM, JoensuuH. 2008. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One, 3:e1885.
6.
PilliT, BrianzoniE, CapoccettiF, CastagnaMG, FattoriS, PoggiuA, RossiG, FerrettiF, GuarinoE, BurroniL, VattimoA, CipriC, PaciniF. 2007. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab, 92:3542–3546.
7.
PaciniF, LadensonPW, SchlumbergerM, DriedgerA, LusterM, KloosRT, ShermanS, HaugenB, CoroneC, MolinaroE, EliseiR, CeccarelliC, PincheraA, WahlRL, LeboulleuxS, RicardM, YooJ, BusaidyNL, DelpassandE, HanscheidH, FelbingerR, LassmannM, ReinersC. 2006. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab, 91:926–932.
8.
TaiebD, SebagF, CherenkoM, Baumstarck-BarrauK, FortanierC, FarmanA, De MiccoC, VaillantJ, ThomasS, Conte-DevolxB, LoundouA, AuquierP, HenryJ, MundlerO. 2009. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation with recombinant human thyrotropin: a randomized controlled study. Clin Endocrinol (Oxf), 71:115–123.
9.
EliseiR, SchlumbergerM, DriedgerA, ReinersC, KloosRT, ShermanSI, HaugenB, CoroneC, MolinaroE, GrassoL, LeboulleuxS, RachinskyI, LusterM, LassmannM, BusaidyNL, WahlR, PaciniF, ChoSY, MagnerJ, PincheraA, LadensonPW. 2009. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metabin press.
10.
HanscheidH, LassmannM, LusterM, KloosRT, ReinersC. 2009. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocr Relat Cancer2009 Jul 23 [Epub ahead of print].
11.
BohuslavizkiKH, KlutmannS, BrennerW, MesterJ, HenzeE, ClausenM. 1998. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. J Clin Oncol, 16:3542–3549.
12.
MendozaA, ShafferB, KaraklaD, MasonME, ElkinsD, GoffmanTE. 2004. Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. Thyroid, 14:133–140.
13.
KimSJ, ChoiHY, KimIJ, KimYK, JunS, NamHY, KimJS. 2008. Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan. Thyroid, 18:325–331.
14.
LevyHA, ParkCH. 1987. Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer. Clin Nucl Med, 12:303–307.
15.
NakadaK, IshibashiT, TakeiT, HirataK, ShinoharaK, KatohS, ZhaoS, TamakiN, NoguchiY, NoguchiS. 2005. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?J Nucl Med, 46:261–266.
16.
LamMG, van IsseltJW. 2005. Re: does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?J Nucl Med, 46:2118–2119.
17.
Van NostrandD, AtkinsF, BandaruVV, ChennupatiSP, MoreauS, BurmanK, WartofskyL. 2009. Salivary gland protection with sialagogues: a case study. Thyroid, 19:1005–1008.
18.
MandelSJ, MandelL. 2003. Radioactive iodine and the salivary glands. Thyroid, 13:265–271.
19.
ShenDH, KloosRT, MazzaferriEL, JhiangSM. 2001. Sodium iodide symporter in health and disease. Thyroid, 11:415–425.
20.
LeonardJP, SiegelJA, GoldsmithSJ. 2003. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Cancer Invest, 21:241–252.
21.
AlexanderC, BaderJB, SchaeferA, FinkeC, KirschCM. 1998. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med, 39:1551–1554.
22.
SawkaAM, ThabaneL, ParleaL, Ibrahim-ZadaI, TsangRW, BrierleyJD, StrausS, EzzatS, GoldsteinDP. 2009. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid, 19:451–457.
23.
Van NostrandD, NeutzeJ, AtkinsF. 1986. Side effects of “rational dose” iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med, 27:1519–1527.
24.
RosarioPW, BorgesMA, PurischS. 2008. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med, 49:1776–1782.
ZettinigG, HanselmayerG, FuegerBJ, HofmannA, PirichC, NeppJ, DudczakR. 2002. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur J Nucl Med Mol Imaging, 29:1428–1432.
30.
KitaT, YokoyamaK, HiguchiT, KinuyaS, TakiJ, NakajimaK, MichigishiT, TonamiN. 2004. Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. Ann Nucl Med, 18:345–349.
31.
CaglarM, TuncelM, AlparR. 2002. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med, 27:767–771.
32.
MalpaniBL, SamuelAM, RayS. 1996. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol Phys, 35:535–540.
33.
AlbrechtHH, CreutzigH. 1976. Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose radio-iodine therapy (author's transl)Rofo, 125:546–551(In German.)
34.
LeeJ, SogutluG, LeardL, ZarnegarR, BaileyJ, GoldenJ, HaysS, KebebewE, DuhQY, ClarkO. 2007. Lung transplantation for pulmonary metastases and radiation-induced pulmonary fibrosis after radioactive iodine ablation of extensive lung metastases from papillary thyroid carcinoma. Thyroid, 17:367–369.
35.
BenuaRS, CicaleNR, SonenbergM, RawsonRW. 1962. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med, 87:171–178.
36.
WangW, LarsonSM, TuttleRM, KalaigianH, KolbertK, SonenbergM, RobbinsRJ. 2001. Resistance of [18F]-flourodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid, 11:1169–1175.
37.
RobbinsRJ, WanQ, GrewalRK, ReibkeR, GonenM, StraussHW, TuttleRM, DruckerW, LarsonSM. 2006. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab, 91:498–505.
KloosRT, EngC, EvansDB, FrancisGL, GagelRF, GharibH, MoleyJF, PaciniF, RingelMD, SchlumbergerM, WellsSAJr.2009. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid, 19:565–612.
40.
HanscheidH, LassmannM, LusterM, ThomasSR, PaciniF, CeccarelliC, LadensonPW, WahlRL, SchlumbergerM, RicardM, DriedgerA, KloosRT, ShermanSI, HaugenBR, CarriereV, CoroneC, ReinersC. 2006. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med, 47:648–654.
